Hodgkin lymphoma

An adequate tissue biopsy is essential. Classical Hodgkin lymphoma (cHL) contains characteristic malignant cells in a larger background of immune cells; a small needle sample can miss the diagnostic pattern. Expert review is useful when the report is equivocal or the course is unusual.

The classical patterns include nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-depleted disease. These names are not the same as the stage. Nodular lymphocyte-predominant disease is biologically different and may be described using B-cell lymphoma terminology in newer classifications.

PET/CT maps disease before treatment. The team also reviews blood counts, organ function, inflammatory markers, performance status and B symptoms: unexplained fever, drenching night sweats or substantial unexplained weight loss. A large mediastinal mass can affect the risk group even in apparently limited disease.

Early favorable, early unfavorable and advanced disease are treatment categories whose definitions differ between study groups. Ask which system is being used. Heart and lung assessment, pregnancy planning and fertility preservation should occur before medicines that may cause lasting harm; severe breathlessness or facial swelling needs prompt assessment.

Short-course chemotherapy with involved-site radiotherapy is an established approach for many early-stage patients. Radiation is planned to limit exposure of the heart, lungs and breast tissue. Avoiding radiation can reduce some late risks but may increase relapse risk, depending on the chemotherapy and risk group.

PET negativity alone is not permission to omit treatment. HD16 found more relapses when radiotherapy was omitted after two ABVD cycles in favorable early disease. HD17 supported omission in PET-negative unfavorable early disease after a specific intensified chemotherapy sequence. These results cannot be interchanged.

Nivolumab plus AVD combines PD-1 blockade with doxorubicin, vinblastine and dacarbazine. The US indication covers previously untreated stage III/IV cHL in adults and children aged 12 years or older. It does not automatically extend to every early-stage patient or younger child.

In S1826, nivolumab-AVD improved progression-free survival compared with brentuximab vedotin-AVD. PET-adapted BrECADD is another important advanced-stage strategy: HD21 compared it with escalated BEACOPP in fit adults aged 18–60. These trials did not compare nivolumab-AVD directly with BrECADD.

Choice also depends on autoimmune illness, infection risk, neuropathy, organ function, fertility goals and access. ABVD or other established approaches may remain appropriate in specific settings. Older or frail adults need an individual plan rather than automatic use of a young-adult intensive regimen.

Interim and end-of-treatment PET answer different questions. Deauville scoring compares uptake with reference tissues; the relevant threshold and action depend on the protocol and time point. Some regimens use PET to reduce chemotherapy, omit bleomycin or decide radiation, while others do not use the same rules.

A residual mass can be scar tissue. Inflammation, infection and immune treatment can also affect uptake. Before declaring resistant disease and moving to intensive salvage, the team may seek biopsy or repeat imaging when clinically safe. New symptoms should be assessed even after a reassuring scan.

Relapse should be confirmed with tissue when feasible. For transplant-eligible patients, salvage treatment aims for a deep metabolic response before high-dose therapy and autologous stem-cell transplantation. PD-1 inhibitors and brentuximab vedotin can be incorporated according to prior exposure, resistance and local availability.

Pembrolizumab has a US adult relapsed/refractory cHL indication; pediatric eligibility is more specific. Relapse after autologous transplant does not mean that all options are exhausted. Immunotherapy, other systemic treatment, radiation and selected allogeneic transplantation may be discussed.

Allogeneic transplantation uses donor immune cells and has different risks from autologous transplantation, including graft-versus-host disease. Prior checkpoint blockade affects its planning. The latest EBMT recommendations retain transplantation as a potentially curative strategy; a response to a new drug alone does not settle whether consolidation is needed.

This disease often behaves more indolently and commonly expresses CD20. Depending on stage and symptoms, options may include observation in selected circumstances, local radiotherapy or anti-CD20-based treatment. The classical Hodgkin pathway should not simply be copied.

A rapidly enlarging site, new systemic symptoms or an unusual relapse can require another biopsy to check for transformation to an aggressive B-cell lymphoma. Long follow-up matters because late relapses and transformation can occur.

Discuss sperm, egg or embryo preservation before treatment whenever possible. HD21 fertility analyses favored BrECADD over escalated BEACOPP on important reproductive outcomes, but a lower population risk does not guarantee preserved fertility for an individual.

Long-term follow-up should match actual exposures: anthracyclines and chest radiation affect cardiovascular risk, neck radiation can affect the thyroid, and some treatments increase later cancer risk. A survivorship plan should record medicines and radiation fields and address fatigue, sexual health, vaccinations and appropriate screening.

CD30-targeted CAR-T is being studied for relapsed/refractory disease, including after standard treatments and around transplantation. A recent multicenter phase I/II report included 44 patients with CD30-positive lymphomas, 33 with Hodgkin lymphoma. Mixed populations and single-arm results do not establish superiority over transplant or approved drugs.

Trial review should establish the exact product, recruiting center, prior-treatment rules, manufacturing time, infection precautions and rescue plan. An anti-CD30 drug and CD30 CAR-T are different treatments; expression of the same target does not make them interchangeable.

Bring the pathology slides or blocks, baseline and response PET/CT images, the exact chemotherapy schedule, cumulative anthracycline exposure, radiation plan and all immune-treatment adverse events. The sequence matters as much as the list of medicines.

Ask: Is the goal cure? Which risk group and PET rule apply? What benefit would radiation or transplantation add? How will fertility and late effects be protected? For a new therapy, clarify whether the proposal is licensed treatment, off-label care or a clinical trial in the treatment country.